Envarsus XR (Tacrolimus) Patent Expiration, LOE Window & CMS Spending

Envarsus XR (Tacrolimus) by Veloxis: FDA Orange Book LOE 2028-08-30, 14 AB generics, $64.0M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVeloxis
FDA Application & PathwayN206406 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-08-30
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$64.0M
2024 Medicare Part D Spend$16.9M
2024 Medicaid Spend$47.2M
Reported Wholesale Price Change (CA SB 17)18 WAC filings (max 20.0% 2-yr change)